FDA Gives Guidance on Pediatric Information in Labeling

News
Article

The agency published guidance on how to determine the placement and content of pediatric information in the labeling of drugs and biologics.

FDA published guidance on March 27, 2019 detailing how to determine the placement and content of pediatric information in drug and biologic product labeling. The recommendations help sponsors ensure that information for pediatric drugs is placed in the proper sections and subsections within labeling, so the information is clear and accessible to healthcare providers.

Specifically, the guidance document addresses information regarding drugs that may be ineffective or unsafe in a specific age group and details different scenarios for the type of information being conveyed. The document also discusses information on inactive ingredients and information from nonclinical toxicity studies in juvenile animals.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.